
TYRA-300 is the first oral селективный FGFR3 ингибитор с IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer клетка lines containing the V555M mutation.
TYRA-300 is the first oral selective FGFR3 inhibitor with IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer cell lines containing the V555M mutation.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.